Patrik Eschricht, CEO of PHI, comments:

"Our HoloMonitor system provides detailed cell information to assess the quality of individual cell samples. Imagine a future where researchers can take a patient's cell sample at the bedside in the hospital and instantly determine its suitability for a clinical trial or cell therapy manufacturing. I believe this is the potential that our cell analysis technology holds.

Imagine, if this is possible, our technology could optimize the efficiency of clinical trials and cell therapy manufacturing processes, reduce costs, and make regenerative medicine more accessible and affordable-we would not use a cell therapy production site to manufacture a treatment that won't work and would not spend money on samples that won't be good enough."

PHI has partnered with UCL, a leading academic institution in England, to provide its latest live cell imaging system, HoloMonitor® M4FL. Through this partnership, PHI takes an active first step in further investigating this enormous potential market in which HoloMonitor products could be positioned directly at patient bedsides in hospitals-however, acknowledging that understanding the full possibilities is still at a very early stage.

"I'm very pleased with our new collaboration with UCL, which allows us to explore more the possibilities of our QPI technology for clinical applications and understand how it could make advanced regenerative treatments more accessible and cost-effective," Eschricht added.